192 related articles for article (PubMed ID: 37673823)
1. Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism.
Feng HG; Wu CX; Zhong GC; Gong JP; Miao CM; Xiong B
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15879-15898. PubMed ID: 37673823
[TBL] [Abstract][Full Text] [Related]
2. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
3. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
4. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
5. LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma.
Song XZ; Ren XN; Xu XJ; Ruan XX; Wang YL; Yao TT
Technol Cancer Res Treat; 2020; 19():1533033820957023. PubMed ID: 32910747
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
7. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
Wang H; Chen M; Yang C; Hu H; Jiang Y; Yang F; Lv L
Arch Biochem Biophys; 2023 Jul; 743():109661. PubMed ID: 37268273
[TBL] [Abstract][Full Text] [Related]
8. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
[TBL] [Abstract][Full Text] [Related]
9. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].
Shang L; Jiang W; Zhang J; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909
[TBL] [Abstract][Full Text] [Related]
10. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
11. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
14. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway.
Man J; Zhou W; Zuo S; Zhao X; Wang Q; Ma H; Li HY
Biochem Pharmacol; 2023 Jul; 213():115615. PubMed ID: 37211171
[TBL] [Abstract][Full Text] [Related]
15. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma.
Rahmani F; Ziaeemehr A; Shahidsales S; Gharib M; Khazaei M; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
J Cell Physiol; 2020 May; 235(5):4146-4152. PubMed ID: 31663122
[TBL] [Abstract][Full Text] [Related]
16. MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway.
Wang L; Cui M; Qu F; Cheng D; Yu J; Tang Z; Cheng L; Wei Y; Wu X; Liu X
Curr Pharm Des; 2021; 27(29):3244-3250. PubMed ID: 34126886
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
18. KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.
Lu S; Liu Y; Tian S; He Y; Dong W
Exp Cell Res; 2023 May; 426(1):113564. PubMed ID: 36948354
[TBL] [Abstract][Full Text] [Related]
19. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
